



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	354860	NUTRA-LIFE JOINT FORMULA
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Vitaco Health Australia Pty Ltd	
<b>Postal Address</b>	PO Box 399, NORTH RYDE BC, NSW, 1670 Australia	
<b>ARTG Start Date</b>	12/02/2021	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . NUTRA-LIFE JOINT FORMULA

Product Type	Single Medicine Product	Effective Date	22/06/2022
--------------	-------------------------	----------------	------------

### Permitted Indications

- Antioxidant/Reduce free radicals formed in the body
- Maintain/support collagen formation
- Maintain/support general health and wellbeing
- Maintain/support connective tissue health
- Aid/assist/helps connective tissue production/formation
- Maintain/support bone health
- Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis
- Helps maintain/supports healthy joint cartilage growth/development/production
- Maintain/support joint health
- Maintain/support joint mobility/flexibility
- Decrease/reduce/relieve mild joint pain/soreness
- Maintain/support blood capillary health
- Maintain/support blood vessel health
- Aid/assist/helps protein synthesis in the body
- Helps prevent dietary (state vitamin/mineral/nutrient) deficiency
- Maintain/support skin health
- Maintain/support skin integrity/structure
- Maintain/support skin regeneration
- Maintain/support wound healing

### Indication Requirements

Product presentation must not imply or refer to any form of arthritis or osteoarthritis unless qualified as mild.  
Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).  
Label statement: If symptoms persist, talk to your health professional.  
Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis.  
Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis.

Public Summary



**Australian Government**  
**Department of Health and Aged Care**  
 Therapeutic Goods Administration

Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Product presentation must only refer to mild joint symptoms.

Product presentation must not imply or refer to circulatory disorders/diseases/conditions e.g. thrombosis.

**Standard Indications**

No Standard Indications included on Record

**Specific Indications**

No Specific Indications included on Record

**Warnings**

Adults only.

The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).

Derived from seafood.

If symptoms persist consult your healthcare practitioner (or words to that effect).

This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.

**Additional Product information**

**Pack Size/Poison information**

<b>Pack Size</b>	<b>Poison Schedule</b>
------------------	------------------------

**Components**

**1 . Formulation 1**

**Dosage Form**                      Capsule, hard

**Route of Administration**      Oral

**Visual Identification**

**Active Ingredients**

<b>ascorbic acid</b>	<b>5.625 mg</b>
<b>borax</b>	<b>4.41 mg</b>
Equivalent: boron	.5 mg
<b>bovine chondroitin sulfate</b>	<b>50 mg</b>
<b>copper gluconate</b>	<b>1.19 mg</b>
Equivalent: copper	167 microgram
<b>glucosamine sulfate sodium chloride</b>	<b>946.86 mg</b>
Equivalent: glucosamine sulfate	750 mg
<b>manganese sulfate monohydrate</b>	<b>3.08 mg</b>
Equivalent: manganese	1 mg
<b>selenomethionine</b>	<b>31.25 microgram</b>
Equivalent: selenium	12.5 microgram
<b>zinc oxide</b>	<b>2.5 mg</b>
Equivalent: zinc	2 mg

**Other Ingredients (Excipients)**

- calcium hydrogen phosphate dihydrate**
- Gelatin**
- magnesium stearate**
- purified water**
- sodium lauryl sulfate**

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.